Antibiotic use for Vibrio infections: important insights from surveillance data

BMC Infectious Diseases

Table 3 Mortality associated with various antibiotic regimens in the treatment of V. vulnificus (n=1599)

	N^a	Crude mortality % (95% CI)	Comparison with Quinolone only p value
CDC treatment recommendation^b
Quinolone only	14/84	16.7 (10.2-26.1)	-
Tetracycline + cephalosporin (all generations)	49/226	21.7 (16.8-27.5)	0.329
Tetracycline + 3^rd generation cephalosporin	39/182^c	21.4 (16.1-28.0)	0.366
Other combinations
Quinolone + cephalosporin (all generations)	24/98	24.5 (17.1-33.9)	0.195
Quinolone + tetracycline	15/95	15.8 (9.8-24.4)	0.874
Quinolone + cephalosporin + tetracycline	15/87	17.2 (10.7-26.5)	0.920
Other single antibiotics
Tetracycline alone	30/145	20.7 (14.9-28.0)	0.456
Cephalosporin alone (all generations)	39/106	36.8 (28.2-46.3)	0.002
Penicillin alone	18/54	33.3 (22.2-46.6)	0.024
No antibiotic	156/305	51.1 (45.6-56.7)	<0.001

^an=399 patients with less common antibiotic regimens not included here, thus numbers do not total to n=1599
^bhttp://www.cdc.gov/vibrio/vibriov.html (accessed 27 June 2014): “Doxycycline (100 mg PO/IV twice a day for 7-14 days) and a third-generation cephalosporin (e.g. ceftazidime 1-2 g IV/IM every eight hours) are generally recommended. A single agent regimen with a fluoroquinolone such as levofloxacin, ciprofloxacin or gatifloxacin, has been reported to be at least as effective in an animal model as combination drug regimens with doxycycline and a cephalosporin”
^cn=182 patients are a subset of the n=226 patients with a tetracycline combined with a cephalosporin

ISSN: 1471-2334